Estimated costs of ADEs vary with methodology used

Estimated costs of ADEs vary with methodology used PharmacoEconomics & Outcomes News 784, p16 - 12 Aug 2017 Estimated costs of ADEs vary with methodology used Estimated costs of adverse drug events (ADEs) in adults in Sweden vary with the methodology used, according to findings of study published in Value in Health. ADEs identified from medical records in a random sample of 4970 Swedish adults over a 3-month period in 2008 were assessed for causality, and their costs were estimated using five evaluation methods: diagnostic code method, main diagnosis method, proportion of registered costs method, resource use method, and unit cost method. Maximum estimated direct healthcare costs due to ADEs ranged from €1538 using the diagnostic code method to €413 770 using the unit cost method. However, the cost per patient ranged from €0 to €500 using the diagnostic code method and unit cost method, respectively, under the most conservative definitions for ADE-related healthcare resource use and causality. "The estimated costs for ADEs were highly affected by the choice of the costing methods, and by applying different thresholds for the uncertainty of a causal connection between the drug and the suspected ADE (step 1 of the cost evaluation) as well as between the ADE and the use of health care resources (step 2). In particular, costing methods based on manual assessment of resource use due to ADEs resulted in higher cost estimates than did methods based on registered diagnoses," said the authors. * 2016 euros Gyllensten H, et al. Comparing Methods for Estimating Direct Costs of Adverse Drug Events. Value in Health : 25 Jul 2017. Available from: URL: https:// doi.org/10.1016/j.jval.2017.06.007 803261497 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Estimated costs of ADEs vary with methodology used

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/estimated-costs-of-ades-vary-with-methodology-used-k5zrEz0vmA
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4227-x
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 784, p16 - 12 Aug 2017 Estimated costs of ADEs vary with methodology used Estimated costs of adverse drug events (ADEs) in adults in Sweden vary with the methodology used, according to findings of study published in Value in Health. ADEs identified from medical records in a random sample of 4970 Swedish adults over a 3-month period in 2008 were assessed for causality, and their costs were estimated using five evaluation methods: diagnostic code method, main diagnosis method, proportion of registered costs method, resource use method, and unit cost method. Maximum estimated direct healthcare costs due to ADEs ranged from €1538 using the diagnostic code method to €413 770 using the unit cost method. However, the cost per patient ranged from €0 to €500 using the diagnostic code method and unit cost method, respectively, under the most conservative definitions for ADE-related healthcare resource use and causality. "The estimated costs for ADEs were highly affected by the choice of the costing methods, and by applying different thresholds for the uncertainty of a causal connection between the drug and the suspected ADE (step 1 of the cost evaluation) as well as between the ADE and the use of health care resources (step 2). In particular, costing methods based on manual assessment of resource use due to ADEs resulted in higher cost estimates than did methods based on registered diagnoses," said the authors. * 2016 euros Gyllensten H, et al. Comparing Methods for Estimating Direct Costs of Adverse Drug Events. Value in Health : 25 Jul 2017. Available from: URL: https:// doi.org/10.1016/j.jval.2017.06.007 803261497 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Aug 12, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off